TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
The FDA approved TRYNGOLZA (olezarsen) as the first and only treatment indicated to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. Clinical data from the Phase 3 CORE and CORE2 studies demonstrated triglyceride reductions of up to 72% and a reduction in acute pancreatitis events of up to 91% compared to placebo.
Key figures
- Drug Name
- TRYNGOLZA (olezarsen)
- Phase Of Trial
- Phase 3
- Nnt overall
- 20
- Tg reduction
- up to 72%
- Nnt high risk
- 4
- Prevalence us
- >3 million
- Pancreatitis event reduction
- up to 91%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.